http://www.abbs.info e-mail:abbs@sibs.ac.cn

ISSN 0582-9879                                          ACTA BIOCHIMICA et BIOPHYSICA SINICA 2003, 35(9): 829-833                                    CN 31-1300/Q

 

XBP-1 Enhances the Transcriptional Activity of Estrogen Receptor ¦Á

DING Li-Hua1,2, YE Qi-Nong1*, ZHU Jian-Hua1, YAN Jing-Hua1, ZHONG Hong-Jun1, WANG Zong-Hua2, HUANG Cui-Fen1

( 1Beijing Institute of Biotechnology, Beijing 100850, China; 2College of Life Sciences, Fujian Agriculture and Forestry University, Fuzhou 350002, China )

 

Abstract        The estrogen receptor (ER¦Á) is a member of a large superfamily of nuclear receptors that regulates the transcription of estrogen-responsive genes. Several recent studies have demonstrated that human X-box binding protein 1 (XBP-1) mRNA expression is associated with ER¦Á status in breast tumors. More recently, two forms of XBP-1 were identified due to their unique splicing. The two splicing variants of XBP-1 were designated XBP-1S and XBP-1U, respectively. In this study, the coding sequences of XBP-1S and XBP-1U were cloned respectively into the expression vector pcDNA3 harboring FLAG epitope, generating the recombinant plasmids pcDNA3-FLAG-XBP-1S and pcDNA3-FLAG-XBP-1U. Western blot analysis showed that both XBP-1S and XBP-1U were expressed in mammalian cells. To determine the effects of XBP-1S and XBP-1U on the transcriptional activity of ER¦Á, MDA-MB-231 breast cancer cells were cotransfected with the expression vectors for ER¦Á and either pcDNA3-FLAG-XBP-1S or pcDNA3-FLAG-XBP-1U. The results indicated that XBP-1S and XBP-1U enhanced ER¦Á-mediated transcriptional activities in a hormone-independent manner. GST pull-down assay showed that both XBP-1S and XBP-1U interacted with ER¦Á. These data suggest that XBP-1S and XBP-1U may play an important role in breast cancer growth and progression through ER¦Á signaling.

 

Key words     estrogen receptor; X-box binding protein 1; transcriptional activity

 

XBP-1ÄÜÌá¸ß´Æ¼¤ËØÊÜÌåER¦ÁµÄת¼»îÐÔ

¶¡Àö»ª1,2      Ò¶ÆåŨ1* Ö콨»ª1   ÑϾ°»ª1   ÖÓºì¾ý1   Íõ×Ú»ª2   »Æ´ä·Ò1

£¨1¾üÊÂҽѧ¿ÆÑ§ÔºÉúÎ﹤³ÌÑо¿Ëù£¬ ±±¾© 100850£» 2¸£½¨Å©ÁÖ´óѧÉúÃü¿ÆÑ§Ñ§Ôº£¬ ¸£ÖÝ 350002£©

 

ÕªÒª      ´Æ¼¤ËØÊÜÌå(ER¦Á)ÊÇÒ»ÖÖºËÊÜÌ壬 µ÷½ÚÓë´Æ¼¤ËØÓйصĻùÒòת¼£¬ ÔÚÈéÏÙ°©µÄ·¢Éú·¢Õ¹¹ý³ÌÖоßÓÐÖØÒª×÷ÓᣠÔÚÈéÏÙ°©ÖУ¬ ÈËXºÐ½áºÏµ°°×1(XBP-1)ÓëER¦Á¹²±í´ï£¬ ²¢ÔÚһЩÈéÏÙÖ×ÁöÖйý±í´ï¡£ ×î½ü·¢ÏÖXBP-1ÓÐÁ½ÖÖ¼ôÇÐÐÎʽ£¬ ¼´XBP-1SºÍXBP-1U£¬ µ«ËüÃÇÔÚER¦ÁÐźÅ;¾¶ÖеÄ×÷Óû¹²»Çå³þ¡£ ·Ö±ð½«XBP-1SºÍXBP-1U±àÂëÐòÁпË¡ÖÁ´øÓÐFLAG±êÇ©µÄpcDNA3ÔØÌåÖУ¬ ¹¹½¨³ÉpcDNA3-FLAG-XBP-1SºÍpcDNA3-FLAG-XBP-1UÖØ×éÖÊÁ£¡£ Western Ó¡¼£·ÖÎö±íÃ÷£¬ ¸ÃÁ½ÖÖXBP-1ÐÎʽÔÚ²¸È鶯Îïϸ°ûÖж¼µÃµ½Á˱í´ï¡£ XBP-1µÄÁ½ÖÖ¼ôÇÐÐÎʽµÄÖØ×éÖÊÁ£·Ö±ðºÍER¦Á±í´ïÔØÌ干תȾÈéÏÙ°©Ï¸°ûMDA-MB-231£¬ ¼ì²â¸ÃÁ½ÖÖ¼ôÇÐÐÎʽ¶ÔER¦Áת¼»îÐÔµÄÓ°Ïì¡£ ½á¹û±íÃ÷£¬ XBP-1SºÍXBP-1UÒÔ¼¤Ëز»ÒÀÀµµÄÐÎʽÌá¸ßER¦ÁµÄת¼»îÐÔ¡£ GST³ÁµíʵÑé±íÃ÷£¬ XBP-1SºÍXBP-1U¾ùÄÜÓëER¦Á½áºÏ¡£ ÕâЩ½á¹ûÌáʾ£¬ XBP-1SºÍXBP-1U¿ÉÄÜͨ¹ýÓ°ÏìER¦ÁÐźÅ;¾¶ÔÚÈéÏÙ°©µÄ·¢Éú·¢Õ¹ÖÐÆðÖØÒª×÷Óá£

 

¹Ø¼ü´Ê ´Æ¼¤ËØÊÜÌå; XºÐ½áºÏµ°°×1£¨XBP-1£©; ת¼»îÐÔ

 

´Æ¼¤ËØÊÜÌå(ER¦Á)»ùÒòº¬ÓÐ8¸öÍâÏÔ×Ó£¬ Æä±àÂëµÄµ°°×ÖÊ·ÖA/B¡¢C¡¢D¡¢EºÍFÎå¸ö¹¦ÄÜÇø£¬ °üÀ¨AF1ºÍAF2Á½¸öת¼¼¤»î½á¹¹Óò¡£ ER¦ÁÊÇÒ»ÖÖÅäÌ壨¼¤ËØ£©ÒÀÀµµÄת¼Òò×Ó£¬ ÅäÌå½áºÏµ½ER¦ÁµÄÅäÌå½áºÏÇøºó£¬ ´ÙʹËüºÍÁíÒ»ER¦Á·Ö×ÓÐγɶþ¾ÛÌ壬 ¸Ã¶þ¾ÛÌåÓë°Ð»ùÒòÆô¶¯×ÓÇøÖеĴƼ¤ËØ·´Ó¦Ôª¼þ£¨ERE£©½áºÏ£¬ ÔÚһϵÁÐÓëER¦Á½áºÏµÄ¹²¼¤»î×Ӻ͹²ÒÖÖÆ×Ó×÷ÓÃÏ£¬ ¼¤»î°Ð»ùÒòת¼ £Û1£Ý¡£ ER¦ÁµÄ¼¤»îÒý·¢Ðí¶àÉúÎïѧЧӦ£¬ Èçϸ°ûÉú³¤¡¢ÓÐË¿·ÖÁÑ¡¢³ÌÐòÐÔËÀÍö£Û2£¬ 3£ÝµÈ¡£

ÈËXºÐ½áºÏµ°°×1(X-box binding protein 1£¬ XBP-1)Óë°Ð»ùÒòÆô¶¯×ÓÐòÁÐÖеÄXºÐ½áºÏ£¬ ¹Ê³ÆÎªXºÐ½áºÏµ°°×1¡£ XBP-1ÊÇÒ»¸ö¼îÐÔÁÁ°±ËáÀ­Á´£¨bzip£©µ°°× £Û4£Ý£¬ ÊÇCREB/ATFת¼Òò×Ó¼Ò×åÖеÄÒ»Ô±¡£ XBP-1ÔÚ³ÉÈË×éÖ¯Öй㷺´æÔÚ¡£ ÔÚÅßÌ¥ÆÚ£¬ XBP-1Ö÷ÒªÔÚÍâ·ÖÃÚÏÙÌå¡¢³É¹Çϸ°û¡¢³ÉÈí¹Çϸ°ûºÍ¸ÎÔàÖбí´ï£Û4£¬ 5£Ý¡£ ÔÚÈ˶à¹ÇËèÁöϸ°ûÖУ¬ XBP-1ÔÚ¶ñÐÔ½¬Ï¸°û·Ö»¯ÖоßÓÐÖØÒª×÷ÓãÛ6£Ý¡£ 10Äêǰ£¬ ¿ÆÑ§¼ÒÃÇÒѿˡµÃµ½XBP-1£Û4£Ý£¬ ²¢Ò»Ö±ÈÏΪֻ´æÔÚÒ»ÖÖÐÎʽ£¬ ¼´XBP-1U¡£ ×î½ü·¢ÏÖ£¬ ÔÚÄÚÖÊÍøÓ¦¼¤Ê±£Û7£¬ 8£Ý£¬ XBP-1U mRNAÓÉIÐÍ¿çĤµ°°×¼¤Ã¸/ºËÌǺËËáÄÚÇÐø£¨type I transmembrane protein kinase/ endoribonuclease,IRE1£©¼ôÇвúÉúÁíÍâÒ»ÖÖÐÎʽ£¬ ¼´XBP-1S¡£ ÕâÖÖеÄÐÎʽ¾ßÓкܸߵÄת¼»îÐÔ£¬ ¼¤»î²¸È鶯ÎïµÄδÕÛµþµ°°×ÖÊÓ¦´ð£¨UPR£©¡£ ÕâÖÖ²»¹æ·¶µÄ¼ôÇÐÐÎʽÔÚXBP-1µÄ165λ°±»ùËá²Ð»ù´¦²úÉúÒÆÂëÍ»±ä¡£ Òò´Ë£¬ XBP-1UºÍXBP-1S·Ö±ðÓÉ260ºÍ376¸ö°±»ùËá×é³É£¬ N¶Ë¾ßÓÐÏàͬµÄbzip½á¹¹Óò¡£

»ùÒòоƬºÍSAGE¼¼Êõ±íÃ÷£¬ ÔÚÈéÏÙ°©ÖУ¬ ER¦ÁÓëXBP-1¹²±í´ï£Û9¡«14£Ý£¬ ÔÚһЩÈéÏÙÖ×ÁöÖУ¬ XBP-1 mRNA±í´ïˮƽÉÏÉý¡£ ÓÉÓÚER¦ÁÔÚÈéÏÙ°©µÄ·¢Éú¡¢·¢Õ¹ÖоßÓÐÖØÒª×÷Ó㬠Òò´ËÑо¿XBP-1¶ÔER¦Áת¼»îÐÔµÄÓ°Ïì¿ÉÄÜΪÈéÏÙ°©µÄÖÎÁÆÌṩеÄÖÎÁưбꡣ ±¾ÊµÑé¿Ë¡µÃµ½ÁËXBP-1µÄÁ½ÖÖ¼ôÇÐÐÎʽ£¬ ¼ì²âÁËÕâÁ½ÖÖ¼ôÇÐÐÎʽ¶ÔER¦Áת¼»îÐÔµÄÓ°Ï죬 Ϊ½øÒ»²½Ñо¿XBP-1ºÍER¦ÁÔÚÈéÏÙ°©ÖеÄ×÷ÓôòÏÂÁË»ù´¡¡£

 

1 ²ÄÁϺͷ½·¨(Materials and Methods)

1.1 ÖÊÁ£ºÍϸ°ûÖê

pERE-LUCÖÊÁ££¬ Ϊº¬´Æ¼¤ËØ·´Ó¦Ôª¼þ£¨ERE£©µÄÓ«¹âËØÃ¸±¨¸æ»ùÒò£¬ ÓÉTSAI Ming-jer²©Ê¿£¨Baylor College of Medicine£©ÔùËÍ¡£ ÈËER¦Á±í´ïÔØÌåpcDNA3-ER¸ù¾ÝÎÄÏ×£Û15£ÝµÄ·½·¨¹¹½¨¡£ ÈéÏÙ°©Ï¸°ûÖêMDA-MB-231ÓÉLEDER Philip ºÍ ZHOU Fen²©Ê¿£¨Harvard Medical School£©ÔùËÍ¡£ SV40ת»¯µÄ293TÉöϸ°ûÓɱ¾ÊÒ±£´æ¡£

1.2 ϸ°ûºÍϸ°ûÅàÑø

293T ºÍMDA-MB-231ϸ°û·Ö±ð²ÉÓú¬10%̥ţѪÇåµÄRPMI1640ºÍDMEMÅàÑø»ùÓÚ37 ¡æ¡¢5%CO2ÅàÑøÏäÄÚ³£¹æÅàÑø¡£
1.3
¿¹Ìå

¿¹FLAGµÄµ¥¿Ë¡¿¹Ì幺×ÔSigma¹«Ë¾¡£ À±¸ù¹ýÑõ»¯ÎïøżÁªµÄÑò¿¹ÊóIgG¹º×ÔVector¹«Ë¾¡£
1.4
·Ö×ÓÉúÎïѧÊÔ¼Á

¸÷ÖÖ·Ö×ÓÉúÎïѧÊÔ¼Á·Ö±ð¹º×ÔNEB¡¢Qiagen¡¢Vector¼°InvitrogenµÈ¹«Ë¾¡£
1.5
ÖØ×éÖÊÁ£µÄ¹¹½¨

·Ö±ð¹¹½¨pcDNA3-FLAG-XBP-1SºÍpcDNA3-FLAG-XBP-1UÖØ×éÖÊÁ£¡£ ÒÔÂѳ²Ë«ÔÓ½»cDNAÎÄ¿â(Clontech¹«Ë¾²úÆ·)Ϊģ°å£¬ ÒÔP1(5¡ä-CGGGATCCATGGTGGTGGTGGCAG-3¡ä)ºÍP2(5¡ä-CCGCTC-GAGTTAGACACTAATCAGCTGG-3¡ä)ΪÒýÎ PCRÀ©ÔöXBP-1S¡£ ÒÔBamHIºÍXhoI˫øÇÐPCR²úÎ ½«PCR²úÎï²åÈ뵽ͬÑù˫øÇеÄpcDNA3-FLAGÔØÌåÖУ¬ ¼´µÃÖØ×éÖÊÁ£pcDNA3-FLAG-XBP-1S¡£ Ϊ¿Ë¡XBP-1U£¬ Ê×ÏÈÀûÓÃÖØ×éPCR¼¼Êõ»ñµÃXBP-1UµÄÈ«³¤±àÂëÇøÐòÁС£ ¼´ÒÔP3(5¡ä-CGGGATCCATGGTGGTGGTGGCAGCCG-3¡ä)ºÍP4(5¡ä-CACCTGCTGCAGAGGTGCACGTAGTCTGAGTGCTGCGGACTCAG-CAG-3¡ä)ΪÒýÎ ÒÔpcDNA3-FLAG-XBP-1SΪģ°å£¬ PCRÀ©ÔöXBP-1UƬ¶Î1£¬ ÒÔP5(5¡ä-CTACGTGCACCTCTGCAGCAGGTGCAGGCCCAGTTGTCAC-3¡ä)ºÍP6(5¡ä-CCGCTCGAGTTAGTTCATTAATGGCTTCCAG-3¡ä)ΪÒýÎ ÒÔpcDNA3-FLAG-XBP-1SΪģ°å£¬ PCRÀ©ÔöXBP-1UƬ¶Î2¡£ ÔÙÒÔP3ºÍP6ΪÒýÎ ÒÔÆ¬¶Î1ºÍ2Ϊģ°å£¬ PCRÀ©ÔöXBP-1UÈ«³¤±àÂëÇøÐòÁС£ PCR²úÎï¾­BamHIºÍXhoI˫øÇкóÁ¬½Óµ½¾­Í¬ÑùøÇеÄpcDNA3-FLAGÔØÌåÖУ¬ ¼´µÃµ½ÖØ×éÖÊÁ£pcDNA3-FLAG-XBP-1U¡£

ÉÏÊö¿Ë¡ËùÓÃPCRÀ©ÔöÌõ¼þ¾ùΪ: 94 ¡æ±äÐÔ1 minºó£¬ °´ÒÔϲÎÊý½øÐÐ25´ÎÑ­»·£º94 ¡æ±äÐÔ1 min£¬ 55 ¡æ¸´ÐÔ1 min£¬ 72 ¡æÑÓÉì2 min¡£ ×îºó72 ¡æÑÓÉì7 min¡£ PCRÀ©ÔöËùÓÃøΪĿǰ±£Õæ¶È×î¸ßµÄpfu DNA¾ÛºÏø¡£ ËùÓÐÖØ×éÖÊÁ£¾­T7ºÍSP6ͨÓÃÒýÎï²âÐò¡£
1.6
²¸È鶯Îïϸ°ûµÄתȾ

ÔÚתȾǰ24 h£¬ Óú¬100 g/LÆÏ¾ÛÌǰü¹üµÄ»îÐÔ̼£¨DCC£©´¦ÀíµḀ̈ţѪÇåºÍÎÞ·ÓºìµÄRPMI1640ÅàÑø»ù½«Ï¸°û½ÓÖÖÔÚ12¿×°åÖÐ(Costar¹«Ë¾²úÆ·)¡£ ½ÓÖÖϸ°ûÃܶÈÒÔתȾʱϸ°ûÃܶȴï90%Ϊ׼¡£ ½«×ÜÁ¿Îª1.0 ¦Ìg DNAÓë80 ¦Ìl RPMI1640ÅàÑø»ù»ìºÏ£¬ ÔÙ½«2.5 ¦Ìl LipofectamineTM2000Óë80 ¦Ìl RPMI1640ÅàÑø»ù»ìºÏ£¬ È»ºó½«ÉÏÊöÁ½ÖÖÈÜÒº»ìºÏ£¬ ÊÒηÅÖÃ20 min£¬ ¼ÓÈëµ½º¬ÓÐ800 ¦Ìl RPMI1640ºÍ10%̥ţѪÇåµÄ12¿×°åÖС£ תȾ4 hºó¼Ó10 nmol/L´Æ¼¤ËØ£¨ÈÜÓÚÎÞË®ÒÒ´¼ÖУ©£¬ ¶ÔÕÕ¼ÓÎÞË®ÒÒ´¼¡£
1.7 Western
Ó¡¼£·ÖÎö

293Tϸ°ûתȾ24 hºó£¬ ÊÕ¼¯Ï¸°û£¬ ¼ÓÈëSDS¼ÓÑù»º³åÒº£¬ Öó·Ð10 min£¬ ÀëÐĺóÈ¡ÉÏÇåÒº½øÐÐSDS-PAGE£¬ µçÓ¾½áÊøºó×ªÒÆÖÁÏõËáÏËÎ¬ËØÄ¤ÉÏ£¬ ÓÃ50 g/LÍÑÖ¬ÄÌ·Û4 ¡æ·â±Õ¹ýÒ¹£¬ È»ºóÓÃ50 g/LÍÑÖ¬ÄÌ·ÛÏ¡Ê͵Ŀ¹FLAGµ¥¿Ë¡¿¹ÌåÊÒÎÂÇáÒ¡1 h£¬ TBSTϴĤ3´Î£¬ ÿ´Î7 min£¬ ¼ÓÈëÓÃ50 g/LÍÑÖ¬ÄÌ·ÛÏ¡Ê͵ÄÀ±¸ù¹ýÑõ»¯ÎïøżÁªµÄÑò¿¹ÊóIgG£¬ ÊÒÎÂÇáÒ¡1 h£¬ TBSTϴĤ3´Î£¬ ÿ´Î7 min£¬ ÓóÃ×ŵ£¨luminol£©ºÍ¹ýÑõ»¯Îperoxide£©(Pierce¹«Ë¾)¸÷1 ml»ìÔÈ,¼Óµ½ÏõËáÏËÎ¬ËØÄ¤ÉÏ·´Ó¦5 min£¬ ѹƬÏÔÓ°¡£
1.8
Ó«¹âËØÃ¸ºÍ¦Â-°ëÈéÌÇÜÕø»îÐԲⶨ

Ó«¹âËØÃ¸»îÐԲⶨ»ù±¾°´Promega¹«Ë¾ËµÃ÷Êé½øÐС£ ´Æ¼¤ËØ»òÎÞË®ÒÒ´¼´¦ÀíתȾϸ°û24 hºó£¬ ÎüµôÅàÑø»ù£¬ ÓÃPBSÏ´1´Î£¬ ¼ÓÈë160 ¦Ìl Áѽ⻺³åÒº£¬ ÊÒÎÂÇáÒ¡15 min£¬ ¹ÎÏÂϸ°û£¬ ÊÕ¼¯µ½1.5 mlÀëÐĹÜÖУ¬ Õðµ´5 min£¬ 4 ¡æ£¬ 12 000 r/minÀëÐÄ3 min£¬ ÊÕ¼¯ÉÏÇåÒº£¬ È¡10 ¦ÌlÓÃÓ«¹â¼Æ²âÁ¿Ó«¹âËØÃ¸»îÐÔ¡£
ÓÃONPG²â¦Â-°ëÈéÌÇÜÕø»îÐÔ¡£ ÉÏÊö50 ¦ÌlÉÏÇåÒºÓë450 ¦Ìl Z»º³åÒº/¦Â-ÛÏ»ùÒÒ´¼ÈÜÒº»ìºÏ£¬ ¼ÓÈë100 ¦Ìl ONPG£¬ 30 ¡æÎÂÓý£¬ Ö±µ½³öÏÖdz»ÆÉ«ÎªÖ¹£¬ ¼ÓÈë250 ¦ÌlŨ¶ÈΪ1 mol/L Na2CO3ÖÕÖ¹ÑÕÉ«·´Ó¦£¬ ÔÚ²¨³¤420 nmϲⶨÑùÆ·AÖµ¡£
1.9 ER¦Á
ת¼»îÐԵIJⶨ

MDA-MB-231ϸ°ûתȾ4 hºó£¬ ¼Ó10 nmol/L´Æ¼¤ËØ£¨ÈÜÓÚÎÞË®ÒÒ´¼ÖУ©£¬ ¶ÔÕÕ¼ÓÎÞË®ÒÒ´¼¡£ 24 hºó,ÀûÓÃÓ«¹âËØÃ¸²â¶¨ER¦Áת¼»îÐÔ¡£ ÿһתȾʵÑéÖУ¬ ͬʱתȾӫ¹âËØÃ¸±¨¸æ»ùÒòERE-LUC(0.2 ¦Ìg)©p±í´ï¦Â-°ëÈéÌÇÜÕøµÄÖÊÁ£(0.1 ¦Ìg)¡¢ER¦Á±í´ïÔØÌåºÍXBP-1Á½ÖÖ²»Í¬¼ôÇÐÐÎʽµÄÖØ×éÖÊÁ£¡£ ¦Â-°ëÈéÌÇÜÕø±¨¸æ»ùÒòÓÃÓÚУÕýϸ°ûתȾЧÂÊ¡£ ת¼¼¤»î»îÐÔΪϸ°ûתȾЧÂÊУÕýºóµÄÓ«¹âËØÃ¸»îÐÔ¡£
1.10 GST-ER¦Á
Èںϵ°°×Ôڴ󳦸˾úÖеıí´ï

½«±í´ï¹Èë׸ÊëÄS×ªÒÆÃ¸-ER¦Á£¨GST-ER¦Á£©Èںϵ°°×µÄÖØ×éÖÊÁ£pGST-ER¦Á (Óɱ¾ÊÒ±£´æ)ºÍ±í´ïGSTµÄ¿ÕÔØÌåpGEX-KG£¨Pharmacia¹«Ë¾£©×ª»¯µ½´ó³¦¸Ë¾úDH5¦ÁÖС£ ת»¯×Ó37 ¡æÕñµ´¹ýÒ¹,ÔÙ°´2 %µÄ½ÓÖÖÁ¿×ª½Ó£¬ 30 ¡æÅàÑø6 hºó£¬ ¼ÓÈëIPTGÖÁÖÕŨ¶ÈΪ0.1 mmol/L£¬ 20 ¡æ¼ÌÐøÓÕµ¼ÅàÑø¹ýÒ¹¡£ ÊÕ¼¯ÉÏÊöÓÕµ¼¾ú£¬ »ù±¾°´Pharmacia¹«Ë¾ËµÃ÷Êé½øÐУ¬ ÀûÓùÈë׸ÊëĿɽáºÏGSTµÄÌØµã£¬ ÓùÈë׸ÊëÄ-Sepharose 4BС¿ÅÁ£´¿»¯GSTÈںϵ°°×¡£ ¼´°´10¡Ã1µÄ±ÈÀý¼ÓÈëϸ°ûÁѽâÒº£¬ ³¬ÉùÆÆË飬 ÀëÐÄÊÕ¼¯ÉÏÇåÒº£¬ ¼ÓÈëÊÊÁ¿¹Èë׸ÊëÄ-Sepharose 4BС¿ÅÁ££¬ ½áºÏ3 h¡£ ÔÙÊÕ¼¯¹Èë׸ÊëÄ-Sepharose 4BС¿ÅÁ££¬ ³ä·ÖÏ´ÍÑδ½áºÏµ°°×ÖÊºó£¬ ¼´µÃµ½½áºÏÓÐGST-ER¦ÁÈںϵ°°×»òGSTµ°°×µÄ¹Èë׸ÊëÄ-Sepharose 4BС¿ÅÁ£¡£
1.11 GST
³Áµí£¨pull-down£©ÊµÑé

°´Promega¹«Ë¾ËµÃ÷Êé½øÐÐÌåÍâ·­Òë¡£ È¡40 ¦Ìl TnT T7 Quick master Mix£¬ 2 ¦Ìl £Û35S£Ý-¼×Áò°±Ëá, 2 ¦Ìg pcDNA3-FLAG-XBP-1SºÍpcDNA3-FLAG-XBP-1UÖØ×éÖÊÁ££¬ ¼ÓË®ÖÁ×ÜÌå»ý50 ¦Ìl£¬ »ìºÏºó30 ¡æË®Ô¡1 h£¬ µÃµ½35S±ê¼Çµ°°×ÖÊXBP-1SºÍXBP-1U¡£ ÔÚ0.5 ml½áºÏ»º³åÒº£¨50 mmol/L Tris-HCl pH 7.5, 150 mmol/L NaCl, 1 mmol/L EDTA, 0.3 mmol/L DTT, 0.1% NP-40¼°µ°°×øÒÖÖÆ¼Á£©ÖмÓÈëÉÏÊöÍ¬Î»ËØ±ê¼Çµ°°×ÖʺÍ10 ¦Ìl ½áºÏÓÐGST-ER¦ÁÈںϵ°°×»òGSTµ°°×µÄSepharose 4BС¿ÅÁ£ÔÚ4 ¡æÏ·´Ó¦¹ýÒ¹¡£ ÓÃÉÏÊö½áºÏ»º³åҺϴµÓС¿ÅÁ£4´Î£¬ ÿ´Î30 min¡£ ÓÃ15 ¦Ìl SDS¼ÓÑù»º³åÒºÖó·ÐÏ´µÓºóµÄС¿ÅÁ£½øÐÐSDS-PAGE£¬ ·ÅÉä×ÔÏÔÓ°¼ì²âÓëER¦Á½áºÏµÄµ°°×ÖÊ¡£
1.12
ͳ¼ÆÑ§·ÖÎö

ÓÃ˫βt¼ìÑ鼯ËãPÖµ¡£

 

2 ½á¹û(Results)

2.1XBP-1Á½ÖÖ¼ôÇÐÐÎÊ½ÖØ×éÖÊÁ£µÄ¹¹½¨

ΪÁ˹¹½¨XBP-1±í´ïÔØÌ壬 ·Ö±ð½«XBP-1SºÍXBP-1UÈ«³¤±àÂëÇøÐòÁпË¡µ½´øÓÐFLAG±êÇ©µÄpcDNA3ÔØÌåÖС£ °´²ÄÁϺͷ½·¨ÖÐËùÊö¹¹½¨XBP-1Á½ÖÖ¼ôÇÐÐÎʽµÄÖØ×éÖÊÁ£pcDNA3-FLAG-XBP-1SºÍpcDNA3-FLAG-XBP-1U¡£ ¾­BamHIºÍXhoIøÇмø¶¨£¬ ·Ö±ðµÃµ½Ô¼1100 bpºÍ780 bpµÄÍâÔ´DNA²åÈëÆ¬¶Î(ͼ1)£¬ ¶ø¿ÕÔØÌåpcDNA3-FLAG¾­Í¬ÑùøÇкóÎÞ²åÈëÆ¬¶Î£¬ ˵Ã÷¿Ë¡³É¹¦¡£ ÖØ×éÖÊÁ£¾­ÐòÁвⶨ֤Ã÷£¬ XBP-1SºÍXBP-1U±àÂëÇøÐòÁÐÍêÈ«ÕýÈ·£¨Êý¾ÝÂÔ£©¡£

 

Fig.1 Restriction analysis of recombinant plasmids

All of the recombinant plasmids were digested with BamHI and XhoI. M, DNA marker; 1, pcDNA3-FLAG; 2, pcDNA3-FLAG-XBP-1S£» 3, pcDNA-FLAG-XBP-1U.

 

2.2 XBP-1Á½ÖÖ¼ôÇÐÐÎʽÔÚ²¸È鶯Îïϸ°ûÖеıí´ï

Èç²ÄÁϺͷ½·¨ÖÐËùÊö£¬ ¿ÕÔØÌå¡¢pcDNA3-FLAG-XBP-1SºÍpcDNA3-FLAG-XBP-1UÖØ×éÖÊÁ£·Ö±ðתȾ293Tϸ°û£¬ ÊÕ¼¯Ï¸°û×ܵ°°×ÖʽøÐÐSDS-PAGE£¬ ÓÃFLAG¿¹Ìå½øÐÐWestern Ó¡¼£·ÖÎö¡£ ½á¹û±íÃ÷£¨Í¼2£©£¬ pcDNA3-FLAG-XBP-1SÔÚÕæºËϸ°ûÖбí´ïÁË·Ö×ÓÁ¿Ô¼50 kDµÄµ°°×ÖÊ£¬ pcDNA3-FLAG-XBP-1U±í´ïÁË·Ö×ÓÁ¿Ô¼35 kDµÄµ°°×ÖÊ£¬ ¶ø¿ÕÔØÌåÎÞµ°°×ÖÊÌõ´ø£¬ ÓëÔ¤ÆÚ½á¹ûÏàͬ¡£

 

Fig.2 Western blotting showing XBP-1S and XBP-1U protein levels in 293T cells

Whole-cell extracts were prepared, and equivalent amounts of each extract were probed with anti-FLAG antibody.1, 293T cells were transfected with 0.5 ¦Ìg pcDNA3; 2, 293T cells were transfected with 0.5 ¦Ìg expression vector XBP-1S; 3, 293T cells were transfected with 0.5 ¦Ìg expression vector XBP-1U.

 

Fig.3 XBP-1S and XBP-1U enhance ER¦Á -mediated transcription activation in MDA-MB-231 cells

Cells were cotransfected with 0.2 ¦Ìg of ERE-LUC, 50 ng of the expression plasmid for ER¦Á, 0.1 ¦Ìg ¦Â-gal expression vector and 0.5 ¦Ìg expression vectors for either XBP-1S or XBP-1U as indicated. Cells were then treated with control vehicle (0.1% ethanol) or 10 nmol/L 17¦Â-estradiol (E2) for 24 h before luciferase assay. The LUC activity obtained on transfection of ERE-LUC and ER¦Á without exogenous XBP-1S and XBP-1U in the absence of E2 was set as 1. Results are expressed as ¡À s for three independent experiments.

 

2.3 ת¼»îÐԵIJⶨ

ÀûÓÃER¦ÁÄÜÓëEREÒ»ÖÂÐòÁнáºÏµÄÌØµã£¬ Ñ¡Óú¬´Æ¼¤ËØ·´Ó¦Ôª¼þµÄÓ«¹âËØÃ¸£¨ERE-LUC£©×÷Ϊ±¨¸æ»ùÒò£¬ ͨ¹ý¼ì²âÓ«¹âËØÃ¸»îÐԲⶨER¦ÁµÄת¼¼¤»î¹¦ÄÜ¡£ Èçͼ3Ëùʾ£¬ ÔÚÈéÏÙ°©Ï¸°ûMDA-MB-231ÖУ¬ Óë¿ÕÔØÌå±È½Ï£¬ ÔÚ²»´æÔڴƼ¤ËØÇé¿öÏ£¬ תȾpcDNA3-FLAG-XBP-1SºÍ pcDNA3-FLAG-XBP-1Uϸ°ûµÄERE-LUC»îÐÔ·Ö±ðԼΪתȾ¿ÕÔØÌåʱµÄ3.0±¶£¨P<0.05£©ºÍ1.5±¶£¨P<0.05£©¡£ ÔڴƼ¤ËØE2ÓÕµ¼Ï£¬ pcDNA3-FLAG-XBP-1SºÍ pcDNA3-FLAG-XBP-1UʹERE-LUC»îÐÔ·Ö±ðÔö¼Óµ½Ô¼11±¶ºÍ6±¶£¬ ¶ø¿ÕÔØÌåpcDNA3-FLAGÔÚͬÑùÌõ¼þϵÄERE-LUC»îÐÔֻΪ5.2±¶£¨P<0.05£©¡£ Òò´Ë£¬ ²»¹ÜÓÐÎÞ¼¤ËØ´æÔÚ£¬ XBP-1SºÍXBP-1U¾ùÄÜʹER¦ÁµÄ»îÐÔÌá¸ß¡£
2.4 ER¦Á
·Ö±ðÓëXBP-1SºÍXBP-1UµÄÏ໥×÷ÓÃ

ÀûÓÃÌåÍâת¼ºÍ·­ÒëżÁªµÄ·½·¨£¬ XBP-1SºÍXBP-1UµÃµ½Á˳ɹ¦·­ÒëºÍ35S±ê¼Ç£¨Í¼4£¬ input£©¡£ ½«GST-ER¦Á´¿»¯µ°°×»òGST·Ö±ðÓëXBP-1SºÍXBP-1U»ìºÏºó½øÐÐGST³Áµí£¨pull-down£©ÊµÑé¡£ ½á¹û±íÃ÷£¨Í¼4£©£¬ XBP-1SºÍXBP-1U¾ùÄÜÓëGST-ER¦Á½áºÏ£¬ ¶øÒõÐÔ¶ÔÕÕGST²»ÄܽáºÏXBP-1SºÍXBP-1U£¬ ˵Ã÷XBP-1SºÍXBP-1UÄÜÌØÒì½áºÏER¦Á¡£

Fig.4 Interaction of XBP-1S and XBP-1U with ER¦Á in vitro

GST pull-down assay was performed as described under ¡°Materials and Methods¡±. Full-length GST-ER¦Á fusion proteins, immobilized on beads, were mixed with in vitro translation reaction mixtures of XBP-1S or XBP-1U as indicated. The bound proteins were subjected to SDS-polyacrylamide gel electrophoresis followed by autoradiography. 1, 10% input; 2, GST; 3, GST-ER¦Á; 4, 10% input; 5, GST; 6, GST-ER¦Á.

 

3 ÌÖÂÛ(Discussion)

»ùÒòоƬºÍSAGE¼¼Êõ±íÃ÷£¬ ÔÚÈéÏÙ°©ÖУ¬ XBP-1ÓëER¦Á¹²±í´ï£Û9¡«14£Ý£¬ ÔÚһЩÈéÏÙÖ×ÁöÖйý¶È±í´ï£Û16£Ý£¬ µ«XBP-1ÔÚER¦ÁÐźÅ;¾¶ÖеÄ×÷Óû¹²»Çå³þ¡£ ÎÒÃÇ·¢ÏÖ£¬ XBP-1ÄÜÌá¸ßER¦ÁµÄת¼»îÐÔ¡£

ER¦Áµ÷½Ú°Ð»ùÒòµÄ±í´ïÐèÒªÅäÌåµÄ½áºÏ¡¢Á×Ëữ¡¢¹²¸¨ÖúÒò×ÓµÄÏ໥×÷ÓãÛ17¡«20£Ý¡£ ÒѾ­·¢ÏÖER¦ÁÓëÐí¶à¹²¸¨ÖúÒò×ÓÏ໥×÷Ó㬠°üÀ¨¹²¼¤»î×Ӻ͹²Ò